Amn Healthcare Services
AMN NYSE Health Care Services Financials FY2016–FY2025
Amn Healthcare Services' revenue fell 8.5% to $2.7 billion in fiscal 2025. Its operating margin was −2.0%, up from −3.4% a year earlier. Free cash flow was $234 million, down 2.4%. The diluted share count rose 0.9%.
Revenue
Total sales reported in the income statement.
$2.7B
8.5%
vs prior year
Operating margin
Operating income as a share of revenue.
−2.0%
1.4 pts
Net income
Profit after all expenses, interest and tax.
−$95.7M
Free cash flow
Cash from operations minus capital spending.
$234M
2.4%
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−2.8%
1.4 pts
Market cap
Last close times the latest diluted share count, so it is approximate.
$1.9B
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
17.9x
On $2.69 EPS (TTM)
What Amn Healthcare Services does
No business description yet.
- Legal name
- AMN HEALTHCARE SERVICES, INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- —
- Accession · CIK
- 0001628280-26-009918
0001142750
Revenue and margins
Amn Healthcare Services had $2.7B of revenue in fiscal 2025, down 8.5% on the year before.
FY16
Revenue $1.9B
FY17
Revenue $2.0B
FY18
Revenue $2.1B
FY19
Revenue $2.2B
FY20
Revenue $2.4B
FY21
Revenue $4.0B
FY22
Revenue $5.2B
FY23
Revenue $3.8B
FY24
Revenue $3.0B
FY25
Revenue $2.7B
Q3 '23
Revenue $854M
Q4 '23
Revenue $818M
Q1 '24
Revenue $821M
Q2 '24
Revenue $741M
Q3 '24
Revenue $688M
Q4 '24
Revenue $735M
Q1 '25
Revenue $690M
Q2 '25
Revenue $658M
Q3 '25
Revenue $635M
Q4 '25
Revenue $748M
Q1 '26
Revenue $1.4B
Q2 '26
Revenue $673M
FY16
Gross 32.6%
Operating 10.1%
Net 5.6%
FCF 5.9%
FY17
Gross 32.4%
Operating 10.7%
Net 6.7%
FCF 6.7%
FY18
Gross 32.6%
Operating 9.5%
Net 6.6%
FCF 9.0%
FY19
Gross 33.5%
Operating 8.0%
Net 5.1%
FCF 8.5%
FY20
Gross 33.1%
Operating 6.2%
Net 3.0%
FCF 9.2%
FY21
Gross 32.9%
Operating 12.0%
Net 8.2%
FCF 6.3%
FY22
Gross 32.7%
Operating 12.3%
Net 8.5%
FCF 11.0%
FY23
Gross 33.0%
Operating 8.9%
Net 5.6%
FCF 7.1%
FY24
Gross 30.8%
Operating −3.4%
Net −4.9%
FCF 8.0%
FY25
Gross 28.4%
Operating −2.0%
Net −3.5%
FCF 8.6%
Gross
Operating
Net
FCF
Q3 '23
Gross 33.9%
Operating 10.2%
Net 6.2%
FCF 16.7%
Q4 '23
Gross 31.9%
Operating 4.2%
Net 1.5%
FCF −8.7%
Q1 '24
Gross 31.4%
Operating 4.9%
Net 2.1%
FCF 7.7%
Q2 '24
Gross 31.0%
Operating 5.1%
Net 2.2%
FCF 9.8%
Q3 '24
Gross 31.0%
Operating 3.2%
Net 1.0%
FCF 6.9%
Q4 '24
Gross 29.8%
Operating −27.6%
Net −25.5%
FCF 7.7%
Q1 '25
Gross 28.7%
Operating 1.8%
Net −0.2%
FCF 12.0%
Q2 '25
Gross 29.8%
Operating −18.8%
Net −17.7%
FCF 10.5%
Q3 '25
Gross 29.1%
Operating 7.5%
Net 4.6%
FCF 2.3%
Q4 '25
Gross 26.1%
Operating 1.1%
Net −1.0%
FCF 9.0%
Q1 '26
Gross 26.8%
Operating 8.5%
Net 4.5%
FCF 40.3%
Q2 '26
Gross 30.6%
Operating 4.0%
Net 3.1%
FCF −29.5%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY16
Net income $106M
FY17
Net income $133M
FY18
Net income $142M
FY19
Net income $114M
FY20
Net income $70.7M
FY21
Net income $327M
FY22
Net income $444M
FY23
Net income $211M
FY24
Net income −$147M
FY25
Net income −$95.7M
Q3 '23
Net income $53.2M
Q4 '23
Net income $12.5M
Q1 '24
Net income $17.3M
Q2 '24
Net income $16.2M
Q3 '24
Net income $7.0M
Q4 '24
Net income −$188M
Q1 '25
Net income −$1.1M
Q2 '25
Net income −$116M
Q3 '25
Net income $29.3M
Q4 '25
Net income −$7.7M
Q1 '26
Net income $62.2M
Q2 '26
Net income $21.2M
FY16
Diluted EPS $2.15
FY17
Diluted EPS $2.68
FY18
Diluted EPS $2.91
FY19
Diluted EPS $2.40
FY20
Diluted EPS $1.48
FY21
Diluted EPS $6.81
FY22
Diluted EPS $9.90
FY23
Diluted EPS $5.36
FY24
Diluted EPS −$3.85
FY25
Diluted EPS −$2.48
Q3 '23
Diluted EPS $1.39
Q4 '23
Diluted EPS $0.37
Q1 '24
Diluted EPS $0.45
Q2 '24
Diluted EPS $0.42
Q3 '24
Diluted EPS $0.18
Q4 '24
Diluted EPS −$4.91
Q1 '25
Diluted EPS −$0.03
Q2 '25
Diluted EPS −$3.02
Q3 '25
Diluted EPS $0.76
Q4 '25
Diluted EPS −$0.19
Q1 '26
Diluted EPS $1.59
Q2 '26
Diluted EPS $0.53
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY16
Return on capital 17.5%
Return on equity 26.6%
Return on assets 10.2%
FY17
Return on capital 17.6%
Return on equity 26.2%
Return on assets 10.9%
FY18
Return on capital 15.9%
Return on equity 23.6%
Return on assets 10.3%
FY19
Return on capital 11.6%
Return on equity 16.6%
Return on assets 6.7%
FY20
Return on capital 7.9%
Return on equity 9.1%
Return on assets 3.3%
FY21
Return on capital 20.3%
Return on equity 33.0%
Return on assets 11.9%
FY22
Return on capital 26.0%
Return on equity 40.3%
Return on assets 14.8%
FY23
Return on capital 12.8%
Return on equity 22.5%
Return on assets 7.3%
FY24
Return on capital −4.2%
Return on equity −19.1%
Return on assets −5.5%
FY25
Return on capital −2.8%
Return on equity −14.2%
Return on assets −4.2%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was $234M in fiscal 2025, 8.6% of revenue. Cash from operations minus capital spending.
FY16
Free cash flow $112M
FY17
Free cash flow $134M
FY18
Free cash flow $192M
FY19
Free cash flow $190M
FY20
Free cash flow $219M
FY21
Free cash flow $252M
FY22
Free cash flow $578M
FY23
Free cash flow $268M
FY24
Free cash flow $240M
FY25
Free cash flow $234M
Q3 '23
Free cash flow $142M
Q4 '23
Free cash flow −$71.0M
Q1 '24
Free cash flow $63.2M
Q2 '24
Free cash flow $72.3M
Q3 '24
Free cash flow $47.4M
Q4 '24
Free cash flow $56.6M
Q1 '25
Free cash flow $82.7M
Q2 '25
Free cash flow $68.8M
Q3 '25
Free cash flow $14.8M
Q4 '25
Free cash flow $67.6M
Q1 '26
Free cash flow $555M
Q2 '26
Free cash flow −$198M
FY16
Cash from operations $134M
Capital spending $22.0M
FY17
Cash from operations $161M
Capital spending $26.5M
FY18
Cash from operations $227M
Capital spending $35.2M
FY19
Cash from operations $225M
Capital spending $35.2M
FY20
Cash from operations $257M
Capital spending $37.7M
FY21
Cash from operations $305M
Capital spending $53.6M
FY22
Cash from operations $654M
Capital spending $75.8M
FY23
Cash from operations $372M
Capital spending $104M
FY24
Cash from operations $320M
Capital spending $80.9M
FY25
Cash from operations $270M
Capital spending $35.6M
Cash from operations
Capital spending
Q3 '23
Cash from operations $172M
Capital spending $29.9M
Q4 '23
Cash from operations −$41.1M
Capital spending $29.9M
Q1 '24
Cash from operations $81.4M
Capital spending $18.1M
Q2 '24
Cash from operations $99.5M
Capital spending $27.3M
Q3 '24
Cash from operations $66.7M
Capital spending $19.3M
Q4 '24
Cash from operations $72.8M
Capital spending $16.2M
Q1 '25
Cash from operations $92.7M
Capital spending $10.0M
Q2 '25
Cash from operations $78.5M
Capital spending $9.8M
Q3 '25
Cash from operations $22.7M
Capital spending $7.9M
Q4 '25
Cash from operations $75.6M
Capital spending $7.9M
Q1 '26
Cash from operations $563M
Capital spending $7.2M
Q2 '26
Cash from operations −$190M
Capital spending $8.5M
Cash from operations
Capital spending
Dividends, buybacks and share count
Amn Healthcare Services returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 0.9%.
FY16
Dividends $0.0M
Buybacks $13.3M
FY17
Dividends $0.0M
Buybacks $20.2M
FY18
Dividends $0.0M
Buybacks $67.0M
FY19
Dividends $0.0M
Buybacks $18.7M
FY20
Dividends $0.0M
Buybacks $0.0M
FY21
Dividends $0.0M
Buybacks $2.7M
FY22
Dividends $0.0M
Buybacks $577M
FY23
Dividends $0.0M
Buybacks $425M
FY24
Dividends $0.0M
Buybacks $0.0M
FY25
Dividends $0.0M
Buybacks $0.0M
Dividends
Buybacks
Q3 '23
Dividends $0.0M
Buybacks $0.0M
Q4 '23
Dividends $0.0M
Buybacks $0.0M
Q1 '24
Dividends $0.0M
Buybacks $0.0M
Q2 '24
Dividends $0.0M
Buybacks $0.0M
Q3 '24
Dividends $0.0M
Buybacks $0.0M
Q4 '24
Dividends $0.0M
Buybacks $0.0M
Q1 '25
Dividends $0.0M
Buybacks $0.0M
Q2 '25
Dividends $0.0M
Buybacks $0.0M
Q3 '25
Dividends $0.0M
Buybacks $0.0M
Q4 '25
Dividends $0.0M
Buybacks $0.0M
Q1 '26
Dividends $0.0M
Buybacks $0.0M
Q2 '26
Dividends $0.0M
Buybacks $0.0M
Dividends
Buybacks
FY16
Diluted shares 0.05B
FY17
Diluted shares 0.05B
FY18
Diluted shares 0.05B
FY19
Diluted shares 0.05B
FY20
Diluted shares 0.05B
FY21
Diluted shares 0.05B
FY22
Diluted shares 0.04B
FY23
Diluted shares 0.04B
FY24
Diluted shares 0.04B
FY25
Diluted shares 0.04B
Value Amn Healthcare Services yourself
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.
Discounted cash flow
Value per share
—
Adds net cash of −$733M and divides by 38.5M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Earnings multiple
Value per share
—
Reference multiples: today 17.8x · peers 25.8x · sector 28.4x.
Balance sheet
Cash, debt and the ratios that show how comfortably Amn Healthcare Services can carry it.
FY16
Cash $10.6M
Debt $359M
FY17
Cash $15.1M
Debt $320M
FY18
Cash $13.9M
Debt $441M
FY19
Cash $83.0M
Debt $617M
FY20
Cash $29.2M
Debt $858M
FY21
Cash $181M
Debt $842M
FY22
Cash $64.5M
Debt $844M
FY23
Cash $32.9M
Debt $1.3B
FY24
Cash $10.6M
Debt $1.1B
FY25
Cash $34.0M
Debt $767M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $181M | $64.5M | $32.9M | $10.6M | $34.0M |
| Debt incl. finance leases | $842M | $844M | $1.3B | $1.1B | $767M |
| Net debt / EBITDA | 1.1x | 1.0x | 2.6x | 14.7x | 7.3x |
| Debt / equity | 0.7x | 0.8x | 1.6x | 1.5x | 1.2x |
| Interest coverage | 14.0x | 16.0x | 6.3x | −1.5x | −1.2x |
| Current ratio | 1.4x | 1.3x | 1.3x | 1.1x | 0.9x |
| Quick ratio | 1.4x | 1.3x | 1.3x | 1.1x | 0.9x |
| Total assets | $3.1B | $2.9B | $2.9B | $2.4B | $2.1B |
| Total liabilities | $2.0B | $1.8B | $2.1B | $1.7B | $1.5B |
| Shareholders' equity | $1.2B | $1.0B | $831M | $707M | $642M |
| Net debt (− = net cash) | $661M | $779M | $1.3B | $1.0B | $733M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.1M
1 insider
Of sales under plans
100%
$0.1M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | Mark G FolettaDirector | Sold plan | 3,681 | $31.07 | $0.1M | Form 4 |
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✓ | ✕ | ✕ |
| Cash from operations is positive | ✓ | ✓ | ✓ |
| Return on assets rose | ✕ | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | ✕ | ✓ | ✓ |
| Current ratio rose | ✓ | ✕ | ✕ |
| Share count didn't rise | ✓ | ✓ | ✕ |
| Gross margin rose | ✓ | ✕ | ✕ |
| Revenue rose relative to assets | ✕ | ✕ | ✓ |
| F-score | 6 / 9 | 4 / 9 | 5 / 9 |
| Accruals ratio | −5.6% | −17.5% | −16.2% |
| Altman Z'' | 3.23 | 2.04 | 2.07 |
Similar companies
Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Amn Healthcare Services AMN | $1.9B | −8.5% | −2.0% | 8.6% | −2.8% | 17.9x | 5 | |
| Chemed CHE | $6.8B | 4.1% | 13.4% | 12.9% | 27.3% | 25.8x | 5 | Compare → |
| Hims & Hers Health HIMS | $6.4B | 59.0% | 4.5% | 2.5% | 19.0% | — | 4 | Compare → |
| Concentra Group Holdings Parent CON | $5.0B | 13.9% | 15.4% | 9.1% | 14.9% | 25.3x | 5 | Compare → |
| Alignment Healthcare ALHC | $1.7B | 46.1% | 0.4% | 2.9% | — | 42.4x | 5 | Compare → |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.9B | $2.0B | $2.1B | $2.2B | $2.4B | $4.0B | $5.2B | $3.8B | $3.0B | $2.7B |
| Gross profit | $620M | $644M | $696M | $744M | $792M | $1.3B | $1.7B | $1.2B | $919M | $774M |
| Operating income | $192M | $212M | $203M | $177M | $149M | $478M | $647M | $338M | −$103M | −$55.5M |
| Interest expense | $15.5M | $19.7M | $16.1M | $28.4M | $57.7M | $34.1M | $40.4M | $54.1M | $69.9M | $45.6M |
| Pretax income | $176M | $193M | $187M | $149M | $91.5M | $444M | $607M | $284M | −$173M | −$101M |
| Income tax | $70.3M | $60.2M | $44.9M | $34.5M | $20.9M | $117M | $163M | $73.6M | −$25.6M | −$5.4M |
| Net income | $106M | $133M | $142M | $114M | $70.7M | $327M | $444M | $211M | −$147M | −$95.7M |
| Diluted EPS | $2.15 | $2.68 | $2.91 | $2.40 | $1.48 | $6.81 | $9.90 | $5.36 | −$3.85 | −$2.48 |
| Diluted shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.04B | 0.04B | 0.04B | 0.04B |
| Cash flow | ||||||||||
| Cash from operations | $134M | $161M | $227M | $225M | $257M | $305M | $654M | $372M | $320M | $270M |
| Capital expenditure | $22.0M | $26.5M | $35.2M | $35.2M | $37.7M | $53.6M | $75.8M | $104M | $80.9M | $35.6M |
| Free cash flow | $112M | $134M | $192M | $190M | $219M | $252M | $578M | $268M | $240M | $234M |
| Depreciation and amortization | $29.6M | $32.3M | $41.2M | $58.5M | $94.2M | $104M | $137M | $161M | $174M | $157M |
| Stock-based compensation | $11.4M | $10.2M | $10.8M | $16.2M | $20.5M | $25.2M | $30.1M | $18.0M | $23.3M | $30.7M |
| Acquisitions | $217M | $0.0M | $217M | $248M | $477M | $41.3M | $69.6M | $292M | $0.0M | $0.0M |
| Share buybacks | $13.3M | $20.2M | $67.0M | $18.7M | $0.0M | $2.7M | $577M | $425M | $0.0M | $0.0M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $13.3M | $20.2M | $67.0M | $18.7M | $0.0M | $2.7M | $577M | $425M | $0.0M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $10.6M | $15.1M | $13.9M | $83.0M | $29.2M | $181M | $64.5M | $32.9M | $10.6M | $34.0M |
| Total debt | $359M | $320M | $441M | $617M | $858M | $842M | $844M | $1.3B | $1.1B | $767M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $451M | $474M | $482M | $561M | $534M | $1.3B | $1.1B | $842M | $595M | $545M |
| Current liabilities | $275M | $265M | $307M | $378M | $423M | $969M | $858M | $656M | $546M | $578M |
| Inventory | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Property and equipment, net | $60.0M | $73.4M | $90.4M | $105M | $116M | $127M | $149M | $191M | $186M | $136M |
| Total assets | $1.2B | $1.3B | $1.5B | $1.9B | $2.4B | $3.1B | $2.9B | $2.9B | $2.4B | $2.1B |
| Total liabilities | $738M | $691M | $854M | $1.2B | $1.5B | $2.0B | $1.8B | $2.1B | $1.7B | $1.5B |
| Shareholders' equity | $449M | $563M | $639M | $737M | $820M | $1.2B | $1.0B | $831M | $707M | $642M |
| Margins | ||||||||||
| Gross margin | 32.6% | 32.4% | 32.6% | 33.5% | 33.1% | 32.9% | 32.7% | 33.0% | 30.8% | 28.4% |
| Operating margin | 10.1% | 10.7% | 9.5% | 8.0% | 6.2% | 12.0% | 12.3% | 8.9% | −3.4% | −2.0% |
| EBITDA margin | 11.6% | 12.3% | 11.4% | 10.6% | 10.2% | 14.6% | 15.0% | 13.2% | 2.4% | 3.7% |
| Net margin | 5.6% | 6.7% | 6.6% | 5.1% | 3.0% | 8.2% | 8.5% | 5.6% | −4.9% | −3.5% |
| FCF margin | 5.9% | 6.7% | 9.0% | 8.5% | 9.2% | 6.3% | 11.0% | 7.1% | 8.0% | 8.6% |
| Returns | ||||||||||
| Return on capital | 17.5% | 17.6% | 15.9% | 11.6% | 7.9% | 20.3% | 26.0% | 12.8% | −4.2% | −2.8% |
| Return on capital employed | 24.9% | 22.4% | 18.7% | 12.9% | 8.6% | 23.4% | 30.9% | 15.8% | −5.0% | −3.3% |
| Return on equity | 26.6% | 26.2% | 23.6% | 16.6% | 9.1% | 33.0% | 40.3% | 22.5% | −19.1% | −14.2% |
| Return on assets | 10.2% | 10.9% | 10.3% | 6.7% | 3.3% | 11.9% | 14.8% | 7.3% | −5.5% | −4.2% |
| Growth | ||||||||||
| Revenue growth | 30.0% | 4.5% | 7.4% | 4.0% | 7.7% | 66.5% | 31.6% | −27.7% | −21.3% | −8.5% |
| Net income growth | 29.2% | 25.3% | 6.9% | −19.6% | −38.0% | 363.3% | 35.6% | −52.6% | −169.8% | — |
| EPS growth | 28.0% | 24.7% | 8.6% | −17.5% | −38.3% | 360.1% | 45.4% | −45.9% | −171.8% | — |
| FCF growth | 282.1% | 19.7% | 43.1% | −1.1% | 15.5% | 14.9% | 129.5% | −53.5% | −10.8% | −2.4% |
| Share count change | 0.9% | 0.3% | −1.5% | −2.2% | 0.2% | 0.7% | −6.6% | −12.3% | −2.9% | 0.9% |
| Financial health | ||||||||||
| Net debt / EBITDA | 1.6x | 1.3x | 1.8x | 2.3x | 3.4x | 1.1x | 1.0x | 2.6x | 14.7x | 7.3x |
| Debt / equity | 0.8x | 0.6x | 0.7x | 0.8x | 1.1x | 0.7x | 0.8x | 1.6x | 1.5x | 1.2x |
| Interest coverage | 12.4x | 10.8x | 12.6x | 6.2x | 2.6x | 14.0x | 16.0x | 6.3x | −1.5x | −1.2x |
| Current ratio | 1.6x | 1.8x | 1.6x | 1.5x | 1.3x | 1.4x | 1.3x | 1.3x | 1.1x | 0.9x |
| Quick ratio | 1.6x | 1.8x | 1.6x | 1.5x | 1.3x | 1.4x | 1.3x | 1.3x | 1.1x | 0.9x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.2% | 1.3% | 1.7% | 1.6% | 1.6% | 1.3% | 1.5% | 2.7% | 2.7% | 1.3% |
| Stock comp / revenue | 0.6% | 0.5% | 0.5% | 0.7% | 0.9% | 0.6% | 0.6% | 0.5% | 0.8% | 1.1% |
| Payouts / FCF | 11.9% | 15.1% | 34.9% | 9.9% | 0.0% | 1.1% | 99.8% | 158.2% | 0.0% | 0.0% |
| Quality scores | ||||||||||
| Piotroski F-score | 6.0 | 5.0 | 7.0 | 5.0 | 3.0 | 6.0 | 6.0 | 6.0 | 4.0 | 5.0 |
| Altman Z'' | 2.7 | 3.5 | 3.1 | 2.6 | 2.0 | 3.3 | 4.0 | 3.2 | 2.0 | 2.1 |
| Accruals ratio | −2.7% | −2.3% | −6.2% | −6.5% | −8.7% | 0.8% | −7.0% | −5.6% | −17.5% | −16.2% |
Source: SEC EDGAR XBRL filings (CIK 0001142750). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.